All News
Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew )
Dr. David Liew reviews abstract OP0124 presented at #EULAR2021
https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw
Links:
Dr. John Cush RheumNow ( View Tweet)
RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021
In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment.
https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021
https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof
Links:
Dr. John Cush RheumNow ( View Tweet)
Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC
Richard Conway RichardPAConway ( View Tweet)
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 mg till wk 12
-TP2: cont SEC or switch to PBO till wk 104
⭐️SEC efficacious on JIA ACR30/70
⭐️74% w/ resolution of enthes
⭐️Median T2flare in PBO in TP2 = 453d
LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
What to tell pts about diet?
*⃣Nutrition plays a role in inflammation in RMD & co-morbidities. What you eat matters!
*⃣ LImit salt, replace w/ herbs
*⃣ Consume low glycemic index foods.
Soda ⬆️risk of RA in women
*⃣⬆️omega-3 ⬇️omega-6 (dairy, eggs)
#EULAR2021 @Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Baseline Vitamin D 😎☀️correlated with biologic response in RA pts.
⭐️EULAR good response: 19.6% Vit D >20 vs 4.2%⬇️Vit D
⭐️Remission: 14.4% ⬆️Vit D vs 3.2% ⬇️Vit D
Abs#POS0100
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
MSK US before 1st clinic visit?
Abs#POS0260 showed ⬇️ in time to diagnosis of inflammatory arthritis from 31 to 12 days and ⬇️clinical visits 2.8 to 2.1
How do you use MSK US in your clinic?
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
6. Rheum disease activity was stable with COVID vaccination.
(RA, PsA, axSpA, SLE - total n = 597)
7/
LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)
Treat-to-target is the robust algorithm that dictates all modern RA treatment.
What's the target? Ummmm
We use it in everyone, right? (both doctors & pts say 66%)
We at least use the principles sometimes, right? (86% of us)
[holds up mirror to self]
POS0305 #EULAR2021 @RheumNow https://t.co/A9MXHMYbag
David Liew drdavidliew ( View Tweet)
On choosing an agent for MTX-IR RA:
"(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha
#EULAR2021 @RheumNow https://t.co/C45ey1SrA1
David Liew drdavidliew ( View Tweet)
I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2:
https://t.co/ChDfihnW4f
@LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021
(ping @DrCMcMaster) https://t.co/Pl7yxYfEqr
David Liew drdavidliew ( View Tweet)
I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2:
https://t.co/ChDfihnW4f
@LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021
(ping @DrCMcMaster) https://t.co/Pl7yxYfEqr
David Liew drdavidliew ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy?
⭐️Mean C3 ⬆️28% compared to 1st trimester
⭐️Mean C4 ⬆️ 11% compared to 1st trimester
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
Eric Dein ejdein1 ( View Tweet)
Looking for RA specific coverage? We've got you covered. #EULAR2021
https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2g
Links:
Dr. John Cush RheumNow ( View Tweet)